PHILADELPHIA, Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024, taking place in San Diego, California, November 15 – 19, 2024. Details on the poster presentation at AASLD 2024 are below: Title: Engineered Macrop ...

Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander "Dr. Scadden's renowned expertise as a physician and medical researcher will be incredibly valuable to Carisma, and we are honored to welcome him to our Board of Directors. Ms. Thorell's experience as a public company executive and Board Member of biotech companies will enhance the business capabilities of our Board," said Steven Kelly, President and Chief Executive Officer of Carisma. "These new appointme ...

Nomination triggers a $2 million milestone payment to Carisma The nomination of this Development Candidate leverages Carisma's expertise in engineering chimeric antigen receptor monocytes and macrophages ("CAR-M") with Moderna's mRNA and lipid nanoparticle platform to create a novel in vivo cell therapy for oncology. Pre-clinical data demonstrated that the Development Candidate can successfully create CAR-M directly in vivo, redirecting endogenous myeloid cells to attack cancer cells. Lin Guey, PhD, Chief S ...

Core Insights - Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies using a proprietary macrophage and monocyte cell engineering platform [5] Company Participation - Steven Kelly, President and CEO of Carisma, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on July 9th at 9:10 am ET [1] Event Details - An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event [4]

Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time Carisma stockholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio web conference at https://meetnow.global/MAJJ4AY. Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer ...

Core Insights - Carisma Therapeutics has initiated a Phase 1 clinical trial for CT-0525, the first CAR-Monocyte therapy evaluated in humans for solid tumors [1][2] - Initial data from the trial is expected by the end of 2024, with the trial focusing on patients with HER2-overexpressing solid tumors [1][2] Company Overview - Carisma Therapeutics is a clinical stage biopharmaceutical company specializing in innovative immunotherapies, particularly through engineered macrophages and monocytes [5] - The company is headquartered in Philadelphia, PA, and aims to develop transformative therapies for cancer and other serious diseases [5] Clinical Trial Details - The Phase 1 trial is an open-label study assessing the safety, tolerability, and manufacturing feasibility of CT-0525 [2][4] - The trial will enroll patients with locally advanced or metastatic solid tumors that have progressed on standard therapies, consisting of two dose escalation cohorts [2][4] Scientific Significance - CT-0525 is designed to address challenges in treating solid tumors, such as tumor infiltration and immunosuppression, with potential advantages over previous CAR-Macrophage therapies [4] - The therapy aims to enhance tumor infiltration, increase persistence, and reduce manufacturing time compared to existing treatments [4] Upcoming Presentations - Carisma will present a Trial in Progress poster at the ASCO 2024 Annual Meeting, detailing the design of the CT-0525 Phase 1 trial [3]

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -24.32%. A quarter ago, it was expected that this company would post a loss of $0.56 per share when it actually produced a loss of $0.52, delivering a surprise of 7.14%.Over the last four quarters, the company ha ...

See accompanying notes to unaudited interim consolidated financial statements. CARISMA THERAPEUTICS INC. Notes to the Interim Consolidated Financial Statements In late March 2024, the Company and its board of directors approved a revised operating plan to reduce monthly operating expenses and conserve cash to begin implementation in April 2024. The plan, includes several measures such as, including prioritizing CT0525, the Company's second product, as its lead anti-human epidermal growth factor receptor 2 ( ...

Exhibit 99.1 Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 First Quarter 2024 Highlights and Upcoming Milestones · CT-0508 (Anti-HER2 CAR-Macrophage) o In late March 2024, Carisma made the decision to pause further development of CT-1119, pending additional financing. o O ...

Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a development candidate in the first quarter of 2025 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 Cash and cash equivalents of $56.5 million expected to fund the Company into the ...